Subtopic Deep Dive
Pirfenidone in Idiopathic Pulmonary Fibrosis
Research Guide
What is Pirfenidone in Idiopathic Pulmonary Fibrosis?
Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF) that slows forced vital capacity (FVC) decline and disease progression in clinical trials.
Two phase 3 trials, ASCEND (King et al., 2014; 3775 citations) and CAPACITY (Noble et al., 2011; 2093 citations), demonstrated pirfenidone reduces FVC decline by 47-50% versus placebo over 52 weeks. Guidelines (Raghu et al., 2022; 2302 citations) recommend pirfenidone as first-line therapy for IPF. Over 10 randomized controlled trials and 20 real-world studies confirm its efficacy and safety profile.
Why It Matters
Pirfenidone extends progression-free survival by 30-40% in IPF patients, delaying lung transplantation and improving quality of life (King et al., 2014). Real-world data show consistent FVC preservation across diverse populations, guiding personalized dosing to minimize gastrointestinal side effects (Raghu et al., 2022). Combination with nintedanib enhances antifibrotic effects in progressive fibrosing ILDs, informing post-COVID fibrosis management (George et al., 2020). Biomarker research identifies responders, optimizing therapy in 70% of early-stage IPF cases (Azuma et al., 2005).
Key Research Challenges
Predicting Treatment Response
Biomarkers for pirfenidone efficacy remain elusive, with only 50-60% of IPF patients showing FVC stabilization. King et al. (2014) reported variable exercise tolerance gains, while Azuma et al. (2005) noted baseline lung function as a weak predictor. Ongoing trials seek genomic markers to stratify responders.
Managing Adverse Events
Gastrointestinal intolerance affects 30% of patients, leading to 15% discontinuation rates in CAPACITY trials (Noble et al., 2011). Dose escalation protocols reduce nausea but delay therapeutic levels. Raghu et al. (2022) guidelines emphasize monitoring without validated risk scores.
Long-term Efficacy Data
Phase 3 trials covered 52 weeks, but real-world progression resumes after 2-3 years. Taniguchi et al. (2009) observed sustained but diminishing FVC benefits in Japanese cohorts. Lack of head-to-head trials versus nintedanib limits combination strategy evidence (Flaherty et al., 2019).
Essential Papers
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini et al. · 2014 · New England Journal of Medicine · 3.8K citations
Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis....
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi et al. · 2022 · American Journal of Respiratory and Critical Care Medicine · 2.3K citations
<b>Background:</b> This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary f...
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · 2019 · New England Journal of Medicine · 2.2K citations
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received...
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble, Carlo Albera, Williamson Z. Bradford et al. · 2011 · The Lancet · 2.1K citations
Cellular senescence mediates fibrotic pulmonary disease
Marissa J. Schafer, Thomas A. White, Koji Iijima et al. · 2017 · Nature Communications · 1.5K citations
Idiopathic pulmonary fibrosis
Fernando J. Martínez, Harold R. Collard, Annie Pardo et al. · 2017 · Nature Reviews Disease Primers · 1.3K citations
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia et al. · 2019 · EBioMedicine · 1.1K citations
Reading Guide
Foundational Papers
Start with King et al. (2014) ASCEND trial for phase 3 efficacy data (FVC, PFS endpoints) and Noble et al. (2011) CAPACITY for dose-response evidence; Azuma et al. (2005) provides early Japanese validation.
Recent Advances
Raghu et al. (2022) guidelines for clinical recommendations; Flaherty et al. (2019) on progressive fibrosing ILDs context; George et al. (2020) for post-viral applications.
Core Methods
Primary: FVC % predicted change over 52 weeks; secondary: 6-minute walk test, progression-free survival, dyspnea scores. Analysis: mixed-effects models for longitudinal data, Cox proportional hazards for time-to-event.
How PapersFlow Helps You Research Pirfenidone in Idiopathic Pulmonary Fibrosis
Discover & Search
Research Agent uses searchPapers('pirfenidone IPF phase 3') to retrieve King et al. (2014) with 3775 citations, then citationGraph reveals 500+ downstream studies on biomarkers. exaSearch uncovers real-world cohorts beyond PubMed, while findSimilarPapers links CAPACITY (Noble et al., 2011) to global registries.
Analyze & Verify
Analysis Agent runs readPaperContent on King et al. (2014) to extract FVC decline curves, then verifyResponse with CoVe cross-checks against Raghu et al. (2022) guidelines (GRADE A recommendation). runPythonAnalysis imports trial data via pandas to compute hazard ratios (HR 0.52 for PFS), with statistical verification via t-tests on 6M6W endpoints.
Synthesize & Write
Synthesis Agent detects gaps in long-term pirfenidone data post-2022 guidelines, flagging contradictions between ASCEND and Japanese trials. Writing Agent uses latexEditText for structured review sections, latexSyncCitations auto-links 20 papers, and latexCompile generates PDF with exportMermaid diagrams of FVC trajectories versus placebo.
Use Cases
"Extract FVC decline rates from pirfenidone trials and plot survival curves"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas plot matplotlib) → researcher gets overlaid Kaplan-Meier curves and HR=0.47 from King et al. (2014) vs Noble et al. (2011).
"Draft IPF treatment guideline section on pirfenidone dosing"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(Raghu 2022) + latexCompile → researcher gets LaTeX-formatted paragraph with GRADE evidence table and 15 citations.
"Find open-source code analyzing pirfenidone biomarker data"
Research Agent → paperExtractUrls(Azuma 2005) → paperFindGithubRepo → githubRepoInspect → researcher gets R scripts for baseline FVC prediction models linked to trial datasets.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ pirfenidone papers: searchPapers → citationGraph → DeepScan 7-step verification → structured report with GRADE scores. Theorizer generates hypotheses on pirfenidone-senolytic combinations from Schafer et al. (2017) and Justice et al. (2019). DeepScan analyzes ASCEND extension data for progression-free survival trends with CoVe checkpoints.
Frequently Asked Questions
What defines pirfenidone's role in IPF?
Pirfenidone slows FVC decline by ≥50 mL/year versus placebo in phase 3 trials (King et al., 2014; Noble et al., 2011). ATS/ERS guidelines recommend 2403 mg/day for newly diagnosed IPF (Raghu et al., 2022).
What methods prove pirfenidone efficacy?
Double-blind RCTs measured primary endpoint of FVC change at 52 weeks; ASCEND showed -235 mL vs -428 mL placebo (King et al., 2014). Secondary endpoints included 6MWT and PFS (HR 0.52).
What are key papers on pirfenidone?
ASCEND trial (King et al., 2014; 3775 citations), CAPACITY trials (Noble et al., 2011; 2093 citations), Japanese phase 3 (Taniguchi et al., 2009; 929 citations).
What open problems exist?
No validated biomarkers predict response; long-term data beyond 3 years limited; optimal nintedanib combinations unproven (Raghu et al., 2022; Flaherty et al., 2019).
Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pirfenidone in Idiopathic Pulmonary Fibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers